Meloxicam tablets for dogs and cats and preparation method for meloxicam tablets

A technology for meloxicam and dogs and cats, applied in the field of medicine, can solve the problems of low absorption rate of suspensions, prone to medical accidents, and high prices of imported medicines, and achieves increased dissolution effect, improved palatability, and is convenient to take. Effect

Inactive Publication Date: 2012-07-04
NANJING SBEED BIOTECH
View PDF2 Cites 9 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

The price of imported drugs is relatively high, which is difficult for many dog ​​and cat owners to accept
In addition, the absorption rate of oral suspension is not high, and the bioavailability is low; while the injection is highly irritating to the local area, which can easily cause pain in dogs and cats, and dogs and cats are more sensitive
However, it is illegal to transfer the human preparations to dogs and cats, and the second is that the dosage is difficult to control, which is prone to medical accidents.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Meloxicam tablets for dogs and cats and preparation method for meloxicam tablets
  • Meloxicam tablets for dogs and cats and preparation method for meloxicam tablets

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0094] This embodiment provides a meloxicam tablet for dogs and cats, especially for meloxicam tablets for dogs and cats. The meloxicam for dogs and cats in this embodiment is a tablet-type drug. It mainly consists of the following mass percentages: meloxicam: 0.1-0.6%, lactose: 50-70%, microcrystalline cellulose: 20-40%, hydroxypropyl cellulose 3-5%, sodium citrate: 0.4- 0.6%, crospovidone: 1-5%, pvpK30: 4-8%, aspartame: 0.2-0.8%, magnesium stearate: 0.60-2%.

[0095] Wherein, meloxicam is a kind of enolic acid non-steroidal anti-inflammatory drug, the inventor finds in the research process of the present invention: meloxicam can selectively inhibit cyclooxygenase-2 (COX-2 ), its inhibitory effect on COX-2 is 10-70 times stronger than that on COX-1.

[0096] Specifically, for dogs and cats, when osteoarthritis, rheumatoid arthritis, acute or chronic fasciitis, fracture, soft tissue injury and surgery, etc., will eventually cause local congestion of the body, tissue cell necr...

Embodiment 2

[0117] A meloxicam tablet for dogs and cats, especially for dogs and cats, provided in this practice, includes main ingredients and auxiliary materials, formulated according to the following weight percentages: main ingredient 0.29%, auxiliary materials 99.7%. The meloxicam tablet of the present invention is formulated by the raw material of following mass percentage:

[0118] Meloxicam: 3 grams;

[0119] Lactose: 600 grams;

[0120] Microcrystalline cellulose: 284 grams;

[0121] Hydroxypropyl cellulose: 40 grams;

[0122] Sodium citrate: 5 grams;

[0123] Cross-linked PVP: 30 grams;

[0124] PVPK30: 60 grams;

[0125] Aspartame: 5 grams;

[0126] Magnesium stearate: 10 grams;

[0127] A total of 1500 tablets were produced.

[0128] The preparation method of the meloxicam tablet of the present invention comprises the weighing and mixing of raw materials and the tableting process, and is characterized in that the specific process steps are as follows:

[0129] 1) Put la...

Embodiment 3

[0136] The present embodiment provides a meloxicam tablet for dogs and cats, especially for dogs and cats, including main ingredients and auxiliary materials, formulated according to the following weight percentages: main ingredient 0.1%, auxiliary materials 99.9%.

[0137] The meloxicam tablet of the present invention is formulated by the raw material of following mass percentage:

[0138] Meloxicam: 1 g

[0139] Lactose: 579 grams

[0140] Microcrystalline cellulose: 272 grams

[0141] Hypromellose: 35 grams

[0142] Sodium citrate: 5 grams

[0143] Cross-linked PVP: 33 grams

[0144] PVPK30: 58 grams

[0145] Aspartame: 4 grams

[0146] Magnesium stearate: 13 grams

[0147] A total of 1500 tablets were produced.

[0148] The preparation method of the meloxicam tablet of the present invention comprises the weighing and mixing of raw materials and the tableting process, and is characterized in that the specific process steps are as follows:

[0149] 1) Put lactose, m...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention relates to the field of medicine, and discloses meloxicam tablets for dogs and cats and a preparation method for the meloxicam tablets. The preparation method mainly comprises: a mixing step, a granulation step, a drying step, a granulation straightening step, a granule mixing step and a tabletting step. The meloxicam tablets consist of the following components in percentage by mass: 0.1 to 0.6 percent of meloxicam, 50 to 70 percent of lactose, 20 to 40 percent of microcrystalline cellulose, 3 to 5 percent of hydroxypropyl cellulose, 0.4 to 0.6 percent of sodium citrate, 1 to 5 percent of cross-linked polyvinylpyrrolidone, 4 to 8 percent of polyvinylpyrrolidone (PVP) K30, 0.2 to 0.8 percent of aspartame and 0.60 to 2 percent of magnesium stearate. The meloxicam tablets have small irritation on the intestines and stomach of the dogs and the cats, and are favorable for the absorption of active ingredients.

Description

technical field [0001] The invention relates to the field of medicine, in particular to a meloxicam tablet for dogs and cats and a preparation method thereof. Background technique [0002] Osteoarthritis is a degenerative bone and joint disease in dogs, and it is also a relatively common and frequent disease in dogs. Among dogs over 1 year old, almost one out of every 5 dogs suffers from osteoarthritis of varying degrees, and the incidence increases with age, about 95% of the cases occur in dogs over 5 years old, 50 % Occurs in senior dogs over 10 years of age. Osteoarthritis can occur in dogs of all ages and breeds, and in all joints. Almost half of the cases occur in large dogs, such as German Shepherds, Rottweilers, Labradors, and Golden Retrievers, but they also often occur in smaller Shetland Sheepdogs, Chihuahuas, etc. In recent years, the incidence of canine osteoarthritis has been increasing, which has attracted the attention of veterinary circles all over the wor...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K9/20A61K31/5415A61K47/12A61K47/38A61K47/32A61P29/00A61K31/194
Inventor 高国峰
Owner NANJING SBEED BIOTECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products